Stocks on the move

Real-time Equity news

U.S. stock market report 1009 ET 20Nov2009-Dell shares plummet after results ------------------------------------------------------------------------------

Shares of Dell Inc, the No. 3 maker of personal computers, tumbled 9.3 percent to $14.38 on Friday, a day after the company said quarterly profit plunged 54 percent. Dell cited lower-than-expected sales as it lost market share to competitors engaged in a budding price war in the PC market. For more on this story, see Reuters Messaging:rm://Edward.Krudy.reuters.com@reuters.net 0934 ET 20Nov2009 November option expiration may be tame event ------------------------------------------------------------------------------

This Friday marks the expiration of November options, which could be a calm event since much of the contracts outstanding have been rolled or closed. The absence of any economic data combined with low levels of open interest in expiring November options should make for a rather uneventful expiration on the open, according to a Credit Suisse note to clients. "Our derivatives traders don't see anything huge in terms of open interest imbalances that would create a large opening trade," the note said. The S&P 500 index November 1100 strike went out with a small imbalance with more calls than puts, and the 1095-1075 lines are all generally paired. Looking ahead to the stock option side, there are small open interest imbalances in the downside November strikes in S&P Depository Receipts and iShares Russell 2000 Index with puts over calls. "But given the multiple liquid hedging tools, we don't see much possibility for fireworks, Credit Suisse said.

Reuters Messaging: doris.frankel.reuters.com@reuters.net 0928 EST 20Nov2009-Dendreon up after FDA okays drug application ------------------------------------------------------------------------------

Shares in Dendreon Corp rose 1.9 percent to $28.59 after the company said on Friday the U.S. Food and Drug Administration has accepted its application to market its experimental prostate cancer vaccine and will rule on whether to approve it by May 1, 2010.

The drug, Provenge, is designed to treat men with advanced prostate cancer. For details see.

Reuters Messaging:rm://Edward.Krudy.reuters.com@reuters.net 0918 EST 20Nov2009-JP Morgan raises year-end target on S&P 500 ------------------------------------------------------------------------------

J.P. Morgan Securities raised its year-end target on the Standard & Poor's 500 index to 1160 from 1100, to reflect its higher 2010 earnings expectations.

The brokerage also said that improvement in payrolls, stabilization in home prices, and greater M&A in 2009 versus 2008 could act as potential catalysts and push the index higher. For details see

Reuters Messaging: rodrigo.campos.reuters.com@reuters.net 0913 EST 20Nov2009-P&G repurchasing shares, quiet on potential deals ------------------------------------------------------------------------------

Procter & Gamble Co does not see acquisitions as a core part of its growth plan and has started to buy back shares again, Chief Financial Officer Jon Moeller said on Friday. For details see.

The company is targeting a "meaningful" level of share buybacks, Moeller said, adding the level is likely to be below the $8 billion annual threshold set before the financial crisis.

Reuters Messaging: rodrigo.campos.reuters.com@reuters.net 0858 EST 20Nov2009-Ann Taylor revenue misses Street view ------------------------------------------------------------------------------

Women's clothing retailer AnnTaylor Stores Corp reported lower-than-expected quarterly revenue on Friday and gave a cautious forecast for the current holiday quarter. For details see

Reuters Messaging: rodrigo.campos.reuters.com@reuters.net 0853 EST 20Nov2009-Large shareholders ask Goldman to trim bonuses-report ------------------------------------------------------------------------------

Big shareholders at Goldman Sachs have asked the U.S. bank, which is on track to pay out the biggest bonuses in the company's history, to pass more profit to investors, the Wall Street Journal reported on Friday.

Goldman Sachs spokesman Lucas van Praag said the criticism of bonuses missed the point. For details see.

Reuters Messaging: rodrigo.campos.reuters.com@reuters.net Keywords: MARKETS STOCKSNEWS

COPYRIGHT

Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.